By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The point-of-care (PoC) analyzers are intended for use in medical offices, clinics, hospitals, and laboratories to deliver prompt and precise results at a reasonable cost. By definition, PoC testing takes place in the patient’s presence, allowing for frank communication between the patient and the practitioner.
The Global point of care analyzer market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The launch of Epithod AutoDx, a completely autonomous point-of-care (POC) analyzer that assesses a comprehensive profile of diabetes tests, is being jointly announced by Precision Diabetes, Inc. and DxGen Corp. Hemoglobin A1c (A1C), C-reactive protein, and urine albumin will be the first tests on the initial test menu; further diabetes tests will be introduced soon.
By incorporating Epithod AutoDx into the diabetes product portfolio, they are demonstrating commitment to providing healthcare professionals access to critical clinical diagnostics focused on early detection, prevention, and management of diabetes, prediabetes, and associated complications in point-of-care settings.
They anticipate having the most complete and user-friendly POC diabetes test solution available in the market as we continue to develop the menu for diabetic tests.
As the diabetes epidemic doesn’t abate, the market for POC tests for diabetes keeps growing quickly. As the menu of diabetes tests continues to grow, The Epithod® AutoDx is well positioned to take the lead in this industry.
